SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Gong appoints Liron Shtraichman as Chief R&D Officer

Sequoia raises $10 billion as it dismantles parts of its global operation

Former Amdocs CEO disclosed $22.5 million in share sales before stock plunged, filings show

Nice says Actimize sale process remains ongoing, offers no update on reported $2 billion Brookfield deal

Buzz

Most popular

Daily

Weekly

1

Google expands buyouts while Wiz acquisition helps lift headcount to record levels

2

Nice to lay off 500 employees as it struggles to navigate the AI transition

3

Amdocs shares plunge 44% as T-Mobile dispute threatens revenue

4

Anthropic’s employee bill hit $1.7 billion in one quarter, or $107,000 per worker each month

5

Israeli startup Explorium shuts down after raising more than $127 million

Mori Arkin

5 stories about Mori Arkin

Exalenz Bioscience Acquired for $49M

19.02.20|Golan Hazani

Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!

Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company

19.02.20|Golan Hazani

Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source

סטפן אושמן מנכ"ל Merck

Merck and WuXi AppTec Announce Launch of Biotech Incubator in Israel

20.02.18|Meir Orbach

The incubator program has a five year budget of 20 million euros

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich

The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani

Sol-Gel approached potential underwriters. It aims to go public before the end of the year